论文部分内容阅读
注射药理剂量精氨酸加压素(AVP)和其相关肽以及其他加压物质,能使心房肽免疫活性物质(APir)释放入血,这种心房肽(AP)受激释放与动脉压增加有关。非加压性的加压素类似物1-脱氨-D-AVP(dDAVP)和AVP 合并使用特异性加压拮抗剂都不能使AP 释放入血。生理水平的AVP,抑制利尿并使血管收缩,其药理剂量则刺激心脏内分泌系统释放AP,AP 可导致利尿和血管舒张,拮抗加压素的生理效应。
Injection of a pharmacological dose of arginine vasopressin (AVP) and its associated peptides, as well as other pressurized substances, releases APIR into the bloodstream. This atrial peptide (AP) is stimulated and released with increased arterial pressure related. Unpressurized vasopressin analogues 1-deamination-D-AVP (dDAVP) and AVP combined with specific pressure-sensitive antagonists did not release AP into the bloodstream. Physiological level of AVP, inhibition of diuretic and vasoconstriction, the pharmacological dose is to stimulate the endocrine system to release AP, AP can lead to diuresis and vasodilation, antagonizing the physiological effects of vasopressin.